8-K: Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95, a Mesothelin-Targeting Bispecific Antibody

Context Therapeutics announces the dosing of the first patient in its Phase 1 clinical trial evaluating CT-95, a mesothelin x CD3 T cell engaging bispecific antibody for solid tumors.

Summary

• Context Therapeutics has dosed the first patient in a Phase 1 clinical trial of CT-95, a bispecific antibody targeting mesothelin-expressing cancers.
• CT-95 is designed to redirect T-cell-mediated lysis toward malignant cells expressing MSLN.
• The company anticipates sharing initial data from the CT-95 Phase 1 trial in mid-2026.
• This is Context's second active clinical trial, following the CTIM-76 trial, which targets Claudin 6-positive tumors.
• The Phase 1 trial (NCT06756035) is an open-label study evaluating the safety and efficacy of CT-95 in patients with advanced solid tumors, including ovarian, pancreatic, lung, and mesothelioma cancers.
• The dose escalation portion of the study is expected to enroll up to 30 patients.

Sentiment

Score: 7

Explanation: The announcement is positive as it indicates progress in the clinical development of CT-95. However, it is still early-stage, and the outcome of the trial is uncertain.

Positives

• The initiation of the CT-95 Phase 1 trial represents a significant milestone for Context Therapeutics.
• The company is expanding its clinical pipeline with a second active clinical trial.
• CT-95 has a moderate affinity but high avidity for membrane-bound MSLN, which is intended to minimize the impact of shed MSLN.
• The trial will evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity.

Risks

• The press release contains forward-looking statements that involve substantial risks and uncertainties.
• Actual results could differ materially from those expressed or implied by the forward-looking statements.
• The success of the clinical trial and the potential for regulatory approval are not guaranteed.

Future Outlook

Context Therapeutics anticipates sharing initial data for the CT-95 Phase 1 trial in mid-2026 and continues to advance its clinical pipeline of T cell engaging bispecific antibody therapies.

Management Comments

• Martin Lehr, CEO of Context, stated that the dosing of the first patient in the CT-95 Phase 1 clinical trial represents another step forward in the company's mission to develop next generation precision immunotherapies for solid tumors.
• Martin Lehr also noted that with both CT-95 and CTIM-76 now dosed in initial patients, the company is advancing its clinical pipeline and expanding its leadership in T cell engaging bispecific antibody therapies.

Industry Context

The development of T cell engaging bispecific antibodies is a growing area in cancer immunotherapy, with several companies pursuing similar approaches. Context Therapeutics is positioning itself as a leader in this field with its pipeline of TCE bispecific therapeutics.

Comparison to Industry Standards

• Companies like Amgen (Blincyto) and Roche (Glofitamab) have already seen success with bispecific antibodies, demonstrating the potential of this therapeutic approach.
• Context's CT-95 targets mesothelin, a well-validated cancer target, similar to other companies developing MSLN-directed therapies.
• The Phase 1 trial design, including dose escalation and expansion cohorts, is a standard approach in early-stage clinical development.

Stakeholder Impact

• Positive for shareholders as it demonstrates progress in the company's clinical development program.
• Potential benefit for patients with mesothelin-expressing cancers if CT-95 proves to be safe and effective.
• May positively impact employees through the advancement of the company's pipeline.

Next Steps

• Enrollment of up to 30 patients in the dose escalation portion of the Phase 1 clinical trial.
• Evaluation of the safety and efficacy of CT-95 in subjects with MSLN-expressing advanced solid tumors.
• Sharing initial data from the CT-95 Phase 1 trial in mid-2026.

Key Dates

Keywords

CT-95, Context Therapeutics, Bispecific Antibody, Phase 1 Clinical Trial, Mesothelin, T cell engager, Solid Tumors, CTIM-76, Cancer, Immunotherapy